stockrowIncyte Corporation
INCYIncyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.
- Revenue
- +14.0%
- EPS
- −277.9%
- Free cash flow
- −233.0%
- Total debt
- −10.5%
Quarter to September 2026, against a year earlier
Follow INCY
Alert me
Incyte Corporation (INCY) Return on equity
Incyte Corporation's return on equity over the twelve months to 30 September 2026 was 7.84%, down 22.0 percentage points from fiscal 2025 (29.9%). Over the past ten years it has ranged from −30.6% (fiscal 2017) to 35.3% (fiscal 2016); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of −50.8% and above the Healthcare sector median of −25.9%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 29.9% | 29.11 |
| FY2024 | 0.76% | (11.74) |
| FY2023 | 12.5% | 4.13 |
| FY2022 | 8.37% | (21.36) |
| FY2021 | 29.7% | 41.08 |
| FY2020 | −11.4% | (31.11) |
| FY2019 | 19.8% | 13.60 |
| FY2018 | 6.16% | 36.71 |
| FY2017 | −30.6% | (65.84) |
| FY2016 | 35.3% | 20.70 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | 138.1% |
| ASND Ascendis Pharma A/S compare | 118.4% |
| EXEL Exelixis, Inc. compare | 44.3% |
| GMAB Genmab A/S Sponsored ADR compare | 12.1% |
| INCY Incyte Corporation | 7.84% |
| JAZZ Jazz Pharmaceuticals PLC compare | 5.05% |
| ROIV Roivant Sciences Ltd. compare | −7.33% |
| BNTX BioNTech SE Sponsored ADR compare | −8.29% |
| INSM Insmed, Inc. compare | −72.5% |
| Biotechnology industry median | −50.8% |
| Healthcare sector median | −25.9% |
| Market median | 1.99% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on INCY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement